Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis

Hepatology

Volumn 65, Issue 2, 2017, Pages 631-646

  Das, Sukanta ^a   Maras, Jaswinder Singh ^a   Hussain, Md Shabir ^a   Sharma, Shvetank ^a   David, Paul ^a   Sukriti, Sukriti ^a   Shasthry, Saggere Muralikrishna ^a   Maiwall, Rakhi ^a   Trehanpati, Nirupama ^a   Singh, Tej P ^b   Sarin, Shiv Kumar ^a  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TOLL LIKE RECEPTOR; LCN2 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ARTICLE; CELL STRESS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HEPATITIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN MODIFICATION; RANDOMIZED CONTROLLED TRIAL; SPECTROPHOTOMETRY; VERY ELDERLY; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; LIQUID CHROMATOGRAPHY; LIVER FUNCTION TEST; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PHYSIOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; SEVERITY OF ILLNESS INDEX;

ADULT; CHROMATOGRAPHY, LIQUID; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS, ALCOHOLIC; HUMANS; LIPOCALIN-2; LIVER FUNCTION TESTS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEUTROPHIL ACTIVATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 85007179488     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28897     Document Type: Article

References (41)

1. Jinjuvadia R, Liangpunsakul S, Translational R; Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium. Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States. J Clin Gastroenterol 2015;49:506–511.
2. Liang R, Liu A, Perumpail RB, Wong RJ, Ahmed A. Advances in alcoholic liver disease: an update on alcoholic hepatitis. World J Gastroenterol 2015;21:11893–11903.
3. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol 2014;12:555–564; quiz e531-e552.
4. Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol 2012;56(Suppl. 1):S39–S45.
5. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572–1585.
6. Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol 2015;12:231–242.
7. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 2001;15:1335–1349.
8. Liu M, Dou Y, Sun R, Zhang Y, Liu Y. Molecular mechanisms for alcoholic hepatitis based on analysis of gene expression profile. Hepat Mon 2015;15:e27336.
9. Xu R, Huang H, Zhang Z, Wang FS. The role of neutrophils in the development of liver diseases. Cell Mol Immunol 2014;11:224–231.
10. Beier JI, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 2010;391:1249–1264.
11. Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol 2014;20:17756–17772.
12. Ercegovac M, Jovic N, Simic T, Beslac-Bumbasirevic L, Sokic D, Djukic T, et al. Byproducts of protein, lipid and DNA oxidative damage and antioxidant enzyme activities in seizure. Seizure 2010;19:205–210.
13. Rani V, Deep G, Singh RK, Palle K, Yadav UC. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci 2016;148:183–193.
14. Iwao Y, Anraku M, Hiraike M, Kawai K, Nakajou K, Kai T, et al. The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet 2006;21:140–146.
15. Liu H, Han T, Tian J, Zhu ZY, Liu Y, Li Y, et al. Monitoring oxidative stress in acute-on-chronic liver failure by advanced oxidation protein products. Hepatol Res 2012;42:171–180.
16. Kawakami A, Kubota K, Yamada N, Tagami U, Takehana K, Sonaka I, et al. Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. FEBS J 2006;273:3346–3357.
17. Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol 2013;59:978–983.
18. Oettl K, Stadlbauer V, Petter F, Greilberger J, Putz-Bankuti C, Hallstrom S, et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008;1782:469–473.
19. Domenicali M, Baldassarre M, Giannone FA, Naldi M, Mastroroberto M, Biselli M, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 2014;60:1851–1860.
20. Naldi M, Baldassarre M, Domenicali M, Giannone FA, Bossi M, Montomoli J, et al. Mass spectrometry characterization of circulating human serum albumin microheterogeneity in patients with alcoholic hepatitis. J Pharm Biomed Anal 2016;122:141–147.
21. Gorudko IV, Grigorieva DV, Shamova EV, Kostevich VA, Sokolov AV, Mikhalchik EV, et al. Hypohalous acid-modified human serum albumin induces neutrophil NADPH oxidase activation, degranulation, and shape change. Free Radic Biol Med 2014;68:326–334.
22. Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M. The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005;334:1322–1328.
23. Regazzoni L, Del Vecchio L, Altomare A, Yeum KJ, Cusi D, Locatelli F, et al. Human serum albumin cysteinylation is increased in end stage renal disease patients and reduced by hemodialysis: mass spectrometry studies. Free Radic Res 2013;47:172–180.
24. Bar-Or D, Bar-Or R, Rael LT, Gardner DK, Slone DS, Craun ML. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med 2005;33:1638–1641.
25. Naldi M, Giannone FA, Baldassarre M, Domenicali M, Caraceni P, Bernardi M, et al. A fast and validated mass spectrometry method for the evaluation of human serum albumin structural modifications in the clinical field. Eur J Mass Spectrom (Chichester) 2013;19:491–496.
26. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304–1313.
27. Wheeler DS, Giuliano JS Jr, Lahni PM, Denenberg A, Wong HR, Zingarelli B. The immunomodulatory effects of albumin in vitro and in vivo. Adv Pharmacol Sci 2011;2011:691928.
28. Michelis R, Kristal B, Zeitun T, Shapiro G, Fridman Y, Geron R, et al. Albumin oxidation leads to neutrophil activation in vitro and inaccurate measurement of serum albumin in patients with diabetic nephropathy. Free Radic Biol Med 2013;60:49–55.
29. English D, Andersen BR. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 1974;5:249–252.
30. Baron CP, Refsgaard HH, Skibsted LH, Andersen ML. Oxidation of bovine serum albumin initiated by the Fenton reaction—effect of EDTA, tert-butylhydroperoxide and tetrahydrofuran. Free Radic Res 2006;40:409–417.
31. Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001;60:358–363.
32. Funk WE, Li H, Iavarone AT, Williams ER, Riby J, Rappaport SM. Enrichment of cysteinyl adducts of human serum albumin. Anal Biochem 2010;400:61–68.
33. Nagumo K, Tanaka M, Chuang VT, Setoyama H, Watanabe H, Yamada N, et al. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. PLoS One 2014;9:e85216.
34. Colombo G, Clerici M, Giustarini D, Rossi R, Milzani A, Dalle-Donne I. Redox albuminomics: oxidized albumin in human diseases. Antioxid Redox Signal 2012;17:1515–1527.
35. Momiyama K, Nagai H, Sumino Y. Comparison of the hemodynamics between patients with alcoholic or HCV-related cirrhosis. Hepatogastroenterology 2011;58:2036–2040.
36. Zekanovic D, Ljubicic N, Boban M, Nikolic M, Delic-Brkljacic D, Gacina P, et al. Doppler ultrasound of hepatic and system hemodynamics in patients with alcoholic liver cirrhosis. Dig Dis Sci 2010;55:458–466.
37. Watanabe A, Tomino Y, Yokoyama K, Koide H. Production of hydrogen peroxide by neutrophilic polymorphonuclear leukocytes in patients with diabetic nephropathy. J Clin Lab Anal 1993;7:209–213.
38. Shurtz-Swirski R, Sela S, Herskovits AT, Shasha SM, Shapiro G, Nasser L, et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diabetes Care 2001;24:104–110.
39. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Drueke T, Santangelo F, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003;64:82–91.
40. Dubuquoy L. Lipocalin 2 highlights the complex role of neutrophils in alcoholic liver disease. J Hepatol 2016;64:770–772.
41. Wieser V, Tymoszuk P, Adolph TE, Grander C, Grabherr F, Enrich B, et al. Lipocalin 2 drives neutrophilic inflammation in alcoholic liver disease. J Hepatol 2016;64:872–880.